glp 1 with the least side effects Managing GLP-1 therapy a Clinician Guide | Obesity Action Coalition posted on topic Managing GLP-1/GIP side effects with
Description
Anderson JW, Konz EC, Jenkins DJ
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved these agents for glycaemic control in type 2 diabetes and, in specific formulations and doses (semaglutide as Wegovy and liraglutide as Saxenda), for weight management in adults with obesity or overweight with weight-related comorbidities

Reduce high-sulfur and high-FODMAP foods

10.1016/j.molmed.2024.10.010 Trends Mol

Some healthcare providers may recommend delaying semaglutide until weaning is complete, while others may support cautious use with close monitoring

Compounding drugs can fulfill an important purpose
